Announcement PDF Chairman’s Address 2023 Annual General Mee�ng Good morning all and thank you for joining us today. I’m pleased to share with you my chairman’s address for our FY23 Annual General Mee�ng for Alterity Therapeu�cs. We are hos�ng this mee�ng both in person in Melbourne and virtually, to ensure all of our shareholders, employees and corporate partners are able to join us. We have had a strong year at Alterity with progress on many fronts as we move closer to our goal of improving outcomes for people with parkinsonian disorders, including Mul�ple System Atrophy, or MSA. Let me start by discussing our clinical progress. Most importantly, we successfully completed enrollment in our ATH434-201 Phase 2 clinical trial, a double-blind, placebo controlled study in par�cipants with early-stage MSA. This is a significant milestone for Alterity as we move one step closer to bringing a new, oral therapy to people living with this devasta�ng condi�on. Because MSA is a rare disease with no approved treatments targe�ng the underlying pathology of the disease, the interest in our trial was extremely high and we consequently exceeded our enrollment target. Study treatment will conclude in the fourth quarter of 2024 and the results from the trial will clarify the path forward for poten�al approval of ATH434. The trial is being conducted at over 20 sites in the US, Australia, New Zealand, and Europe. Physicians across the board have received the trial enthusias�cally as they implement Alterity’s novel methods to diagnose, evaluate and treat early-stage MSA. In July, we passed a cri�cal catalyst in the trial when we received feedback from an independent Data Monitoring Commitee who reviewed clinical data from an ini�al cohort of study par�cipants. The commitee expressed no safety concerns and recommended that our trial con�nue without modifica�on. During the year, we also commenced a new and separate Phase 2 clinical trial, known as ATH434-202. This open label Biomarker study will allow us to assess the efficacy of ATH434 in par�cipants with greater MSA severity than in the double-blind study and will give us valuable informa�on for the next phase of development. Because the trial has the same key biomarker endpoint used to assess efficacy in the double-blind study, it may give us an early indica�on of efficacy. Clinical measures important in MSA will also be assessed. And, finally, our bioMUSE natural history study is helping to improve pa�ent selec�on and iden�fy appropriate biomarkers that will inform clinical trials in MSA, including our own ATH434-201 study. The Study con�nues to generate valuable informa�on by assessing a diverse set of biomarkers to augment clinical criteria for MSA that will greatly improve the diagnosis of this devasta�ng disease. Data presented also demonstrated that wearable sensors can quan�fy motor impairment in MSA pa�ents that is not captured by neurological examina�on, an important component to those living with the disease. We also con�nue to generate promising data on our lead asset, ATH434. Earlier this month we presented new data indica�ng that ATH434 can preserve mitochondrial func�on a�er oxida�ve injury and exert direct an�-oxidant ac�vity independent of its iron binding proper�es. While we have long known that ATH434 is able to reduce labile iron, the demonstrated mitochondrial protec�on may reveal addi�onal mechanisms that augment its ability to slow disease progression. Our research team also con�nues to produce novel, patentable compounds covering several neurodegenera�ve diseases. In August 2023, we secured a new composi�on of mater patent in Europe providing broad protec�on over a new class of iron chaperone drug candidates for trea�ng major neurodegenera�ve diseases, including Alzheimer’s and Parkinson’s diseases. In March 2023, we licensed the use of a separate patent family of more than 100 compounds along with our product candidate PBT2, to Professor Colin Masters to advance the compounds for the treatment of Alzheimer’s and related diseases. Professor Masters’ research on the beta amyloid protein that forms the cerebral plaques in Alzheimer’s disease has laid the foundation for extensive research on the disease and recently approved treatments. Our collaboration with Professor Masters broadens the opportuni�es for our clinical development efforts. I would like to thank our CEO Dr Stamler and his execu�ve team as well as our scien�fic and opera�onal staff for their work and dedica�on to advancement of our development programs. To our shareholders, thank you for your support as we gear up for another exci�ng and produc�ve year for Alterity. We look forward to upda�ng you on our progress for fiscal year 2024. Thank you. About Alterity Therapeu�cs Limited Alterity Therapeu�cs is a clinical stage biotechnology company dedicated to crea�ng an alternate future for people living with neurodegenera�ve diseases. The Company’s lead asset, ATH434, has the poten�al to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Mul�ple System Atrophy. Alterity also has a broad drug discovery pla�orm genera�ng patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further informa�on please visit the Company’s web site at www.alteritytherapeu�cs.com. Authorisa�on & Addi�onal informa�on This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: Australia Hannah Howlet we-aualteritytherapeu�cs@we-worldwide.com +61 450 648 064 U.S. Remy Bernarda remy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forwardlooking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forwardlooking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.